Physician profile
Mark Alan Molos
NPI 1427036797
$31,260.58
in general payments reported to CMS, 2019-2025
38 companies · $22.74 in 2025
The $22.74 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $720 · 2021: $25K · 2022: $1,865 · 2023: $2,532 · 2024: $1,063 · 2025: $22.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523 · Education: $94.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.77 |
| Education | $94.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,435.97 | 2021-2022 | |
| Abbvie INC. | $1,392.05 | 2019-2024 | |
| Janssen Biotech, INC. | $985.89 | 2020-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $918.98 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $614.54 | 2019-2024 | Xifaxan, Trulance |
| Mauna Kea Technologies, INC. | $577.44 | 2021-2023 | |
| Celgene Corporation | $352.95 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $280.44 | 2020-2024 | Dificid, Zinplava, Zerbaxa |
| Regeneron Healthcare Solutions, INC. | $263.25 | 2022-2024 | Dupixent |
| Pfizer INC. | $220.82 | 2019-2024 | |
| Lilly USA, LLC | $207.52 | 2023-2024 | Omvoh |
| Daiichi Sankyo INC. | $179.94 | 2019-2024 | Injectafer |
| Ardelyx, INC. | $176.95 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $166.35 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $162.65 | 2020-2023 | Rebyota |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $156.75 | 2021-2024 | Ocaliva |
| Amgen INC. | $143.23 | 2020-2023 | Avsola, Amjevita |
| Qol Medical, LLC | $142.47 | 2023-2024 | Sucraid, Sucraid |
| Organon LLC | $126.25 | 2021-2023 | Renflexis |
| Genzyme Corporation | $119.10 | 2022-2025 | |
| Alfasigma USA, INC. | $87.53 | 2020-2022 | |
| Redhill Biopharma INC. | $73.89 | 2020-2022 | |
| Celltrion USA INC. | $72.52 | 2023-2024 | Zymfentra, Yuflyma |
| Romark Laboratories, Lc | $71.85 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $60.10 | 2021-2024 | Riteclip, Biopsy Forceps |
| Alnylam Pharmaceuticals INC. | $42.01 | 2022 | |
| Pharmacosmos Therapeutics INC. | $39.35 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $29.62 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $23.02 | 2024 | Voquezna |
| Sandoz INC. | $20.17 | 2024 | Hyrimoz |
| Ucb, INC. | $19.91 | 2019 | |
| La Jolla Pharmaceutical Company | $17.88 | 2021 | |
| Boston Scientific Corporation | $17.86 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.88 | 2021 | |
| Braintree Laboratories, INC. | $14.23 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $11.86 | 2022 | |
| Endo Pharmaceuticals INC. | $11.58 | 2021 | |
| Endogastric Solutions, INC | $7.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Molos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.